Unlocking Precision Medicine with Lower-cost Genomics

New, more affordable technologies offer researchers a deeper understanding of the genetic mutations that cause disease.

An advanced cancer patient receives two more years of life because his doctors found a clinical trial drug built for the mutation-fueled molecular pathway that drove his disease. A diagnostic odyssey comes to a halt, yielding answers for the parents of a child with a rare genetic disease. A MRSA outbreak doesn’t happen at a hospital because the pediatric unit, with the help of the pathology department, finds the source and quickly contains it. 

"Even in the case of novel immunotherapy drugs, having a better understanding of the predictive and prognostic biomarkers for doctors to determine the right combination therapies for each patient requires deeper discovery."


- Bryce Olson
Global Marketing Director for
Health and Life Sciences, Intel

"As the demand for genome sequencing grows, so does the amount of data that must be processed, stored, and managed."


- Jennifer Esposito
Worldwide General Manager,
Health and Life Sciences, Intel

"Faster analytics is always a priority, but the next big requirement is for research institutions and clinics to reliably predict a genomics cluster's throughput."


- Dr. Michael McManus
Senior Health and Life Sciences
Solution Architect at Intel

Emerging technologies, aging populations, and heated public policy debates are bringing elaborate changes to the global healthcare industry. Get a step-by-step blueprint to leveraging precision medicine and genomics to capture market share in these turbulent times.

Get the report

See how technology is ushering in a new era of business, driving innovation that will help industries become smarter, more efficient, and more connected than ever.

Learn more

Understand how Intel technology is using data and patient DNA to combat disease, tailor treatment, and create more collaborative care between health professionals and patients.

Learn more